. Author manuscript; available in PMC: 2019 Nov 1.

Published in final edited form as: Clin Transl Oncol. 2018 May 7;20(11):1474–1483. doi: 10.1007/s12094-018-1888-2

Table 3.

Changes in Tumor-Based Markers in Evaluable MK-2206-Treated Patients (n=7) and Untreated Controls (n=5)

Variable	Mean treatment Pre-MK-2206 Core (SD)	Mean treatment Post-MK-2206 Surgery (SD)	Paired t test p-value^a	Mean Control Core (SD)	Mean Control Surgery (SD)	Paired t test p-value^a	Overall t test p-value^b
Ki-67 (%)	13 (23)	12 (23)	0.59	12 (16)	8 (7)	0.37	0.47
PAKT (%)	25 (29)	0 (0)	0.06^**	35 (35)	1 (1)	0.09^**	0.65
pS6 (%)	41 (36)	26 (31)	0.20	45 (24)	48 (28)	0.89	0.41
PTEN (%)	83 (11)	79 (15)	0.20	68 (33)	78 (11)	0.55	0.91
Stathmin (%)	41 (22)	42 (26)	0.92	46 (32)	52 (31)	0.18	0.51

Paired T-test comparing changes within group (example: pre-MK-2206-treated core versus post-MK-2206-treated surgical tissue)

Two-sided t-test comparing changes between MK-2206-treated samples versus control

Paired t-test, significance defined as p < 0.05

^**

Paired t-test, trend toward significance